utidelone
Small moleculeexperimental
Epothilones are a class of potential cancer drugs. Like taxanes, they prevent cancer cells from dividing by interfering with tubulin, but in early trials, epothilones have better efficacy and milder adverse effects than taxanes. — Wikipedia
Clinical trial activity
31 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
27
Phase 3
7
Phase 4
0
Earliest trial started Mar 4, 2019 (NCT03693547)
Timeline
Indications
Studied for
- Bile Duct Neoplasms · Phase 2
- Breast Neoplasms · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Transitional Cell · Phase 2
- Esophageal Neoplasms · Phase 2/Phase 3
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Neoadjuvant Therapy · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Stomach Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 3
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEpothilone ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07044349 | Phase 2 | Sep 30, 2025 | Biostar |
| NCT07088263 | Phase 3 | Aug 4, 2025 | Sun Yat-Sen University |
| NCT06764940 | Phase 2 | Jul 14, 2025 | Biostar |
| NCT06973421 | Phase 2 | Jul 1, 2025 | Fudan University |
| NCT07021261 | Phase 3 | Jun 16, 2025 | Fudan University |
| NCT06841679 | Phase 2/Phase 3 (Phase 3) | May 1, 2025 | Biostar |
| NCT06683703 | Phase 2 | Dec 1, 2024 | Biostar |
| NCT06730581 | Phase 2 | Dec 1, 2024 | Biostar |
| NCT06510465 | Phase 2 | Aug 1, 2024 | Jiao Tong University |
| NCT06598046 | Phase 2 | Jun 19, 2024 | Henan Medical University |
| NCT06458413 | Phase 2 | Jun 5, 2024 | Biostar, Henan Medical University |
| NCT06355037 | Phase 2 | May 20, 2024 | Fudan University |
| NCT06355024 | Phase 2 | Apr 10, 2024 | Fudan University |
| NCT06125080 | Phase 2 | Oct 30, 2023 | Huazhong University of Science and Technology |
| NCT05983094 | Phase 2 | Sep 1, 2023 | China Medical University, Chinese Academy of Medical Sciences |
| NCT05700084 | Phase 1 | Jun 9, 2023 | Biostar, Chinese Academy of Medical Sciences |
| NCT05681000 | Phase 1 | Jun 9, 2023 | Biostar, University of Southern California |
| NCT05895864 | Phase 2 | Jun 7, 2023 | Sun Yat-Sen University |
| NCT05673629 | Phase 3 | May 30, 2023 | Biostar, Fudan University |
| NCT05866510 | Phase 2 | May 15, 2023 | Biostar, Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Peking University |
Showing 20 of 31 trials
Page 1 / 2
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biostar | For profit | 16 | 13 | 3 | 2019 |
| Fudan University | Academic/Hospital | 6 | 5 | 2 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 5 | 4 | 2 | 2019 |
| Henan Medical University | Academic/Hospital | 4 | 4 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 3 | 1 | 2 | 2019 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 1 | 2 | 2023 |
| Jiao Tong University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 1 | 0 | 1 | 2023 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Tongji University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2023 |
13 organizations
Page 1 / 1